Federal contract award
75N91021F00002
TARGETING STAT3 TO PREVENT COLORECTAL CANCER SECONDARY TO INFLAMMATORY BOWEL DISEASE
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | NIH NCI |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AN12 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH |
| Parent award / vehicle | 75N91019D00021 |
| Set-aside | Not reported |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $930.2K |
| Current contract value | $930.2K |
| Potential contract value / ceiling | $930.2K |
| Start date | Sep 16, 2021 |
| Current end date | Mar 15, 2025 |
| Potential end date | Sep 15, 2025 |
| Latest award activity | Nov 20, 2025 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 8 of 8 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Nov 20, 2025 | P00007 | $-2.7K | BASE CONTRACT TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY & INTERMEDIATE BIOMARKERS TASK ORDER TITLE: TARGETING STAT3 TO PREVENT COLORECTAL CANCER SECONDARY TO INFLAMMATORY BOWEL DISEASE |
| Mar 6, 2025 | P00006 | $0 | BASE CONTRACT TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY & INTERMEDIATE BIOMARKERS TASK ORDER TITLE: TARGETING STAT3 TO PREVENT COLORECTAL CANCER SECONDARY TO INFLAMMATORY BOWEL DISEASE |
| Aug 21, 2024 | P00005 | $0 | BASE CONTRACT TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY & INTERMEDIATE BIOMARKERS TASK ORDER TITLE: TARGETING STAT3 TO PREVENT COLORECTAL CANCER SECONDARY TO INFLAMMATORY BOWEL DISEASE |
| Aug 10, 2023 | P00004 | $0 | BASE CONTRACT TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY & INTERMEDIATE BIOMARKERS TASK ORDER TITLE: TARGETING STAT3 TO PREVENT COLORECTAL CANCER SECONDARY TO INFLAMMATORY BOWEL DISEASE |
| Jun 5, 2023 | P00003 | $0 | BASE CONTRACT TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY & INTERMEDIATE BIOMARKERS TASK ORDER TITLE: TARGETING STAT3 TO PREVENT COLORECTAL CANCER SECONDARY TO INFLAMMATORY BOWEL DISEASE |
| Sep 12, 2022 | P00002 | $0 | BASE CONTRACT TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY & INTERMEDIATE BIOMARKERS TASK ORDER TITLE: TARGETING STAT3 TO PREVENT COLORECTAL CANCER SECONDARY TO INFLAMMATORY BOWEL DISEASE |
| Dec 14, 2021 | P00001 | $0 | TARGETING STAT3 TO PREVENT COLORECTAL CANCER SECONDARY TO INFLAMMATORY BOWEL DISEASE |
| Sep 13, 2021 | 0 | $932.9K | TARGETING STAT3 TO PREVENT COLORECTAL CANCER SECONDARY TO INFLAMMATORY BOWEL DISEASE |
Research next steps
- Verify whether remaining options may extend performance beyond the current end date.
- Confirm the ordering vehicle and your eligibility or a qualified teaming route.
- Review the award scope and buyer evidence before making a bid/no-bid decision.